Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. Rhythm's lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm supports The Genetic Obesity Project (GeneticObesity.com) and the GO-ID Genotyping Study (GeneticObesityID.com).